APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dermatological Non-Steroidal Anti-Inflammatory Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173983520328 December 2025191 pages

Choose your research edition.

Industry ResearchDermatological Non-Steroidal Anti-Inflammatory Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Dermatological Non-Steroidal Anti-Inflammatory Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dermatological Non-Steroidal Anti-Inflammatory Drugs include LEAD CHEMICAL, Merck KGaA, Verona Pharma, Arcutis, GlaxoSmithKline PLc, Huadong Medicine, Pfizer Inc., Roche and MSD, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatological Non-Steroidal Anti-Inflammatory Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatological Non-Steroidal Anti-Inflammatory Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Company

LEAD CHEMICAL

Merck KGaA

Verona Pharma

Arcutis

GlaxoSmithKline PLc

Huadong Medicine

Pfizer Inc.

Roche

MSD

Genzyme Co.

Shapuaisi

Sato Pharmaceutical

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Type

Ketotifen

Ketoconazole

Phthalin Butan

Tacrolimus

Prednisone

Loratadine

Cyclosporine A

Others

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Application

Hospital

Clinic

Others

Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatological Non-Steroidal Anti-Inflammatory Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Non-Steroidal Anti-Inflammatory Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatological Non-Steroidal Anti-Inflammatory Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dermatological Non-Steroidal Anti-Inflammatory Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dermatological Non-Steroidal Anti-Inflammatory Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dermatological Non-Steroidal Anti-Inflammatory Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Trends Table 2. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Drivers Table 3. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Opportunities and Challenges Table 4. Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Restraints Table 5. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Manufacturers Table 9. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Manufacturers, Product Type & Application Table 13. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ketotifen Table 17. Major Manufacturers of Ketoconazole Table 18. Major Manufacturers of Phthalin Butan Table 19. Major Manufacturers of Tacrolimus Table 20. Major Manufacturers of Prednisone Table 21. Major Manufacturers of Loratadine Table 22. Major Manufacturers of Cyclosporine A Table 23. Major Manufacturers of Others Table 24. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type 2021 VS 2025 VS 2032 (Units) Table 25. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type (2021-2026) & (Units) Table 26. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type (2027-2032) & (Units) Table 27. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Type (2021-2026) Table 28. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Type (2027-2032) Table 29. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 30. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type (2021-2026) & (Units) Table 31. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type (2027-2032) & (Units) Table 32. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Clinic Table 36. Major Manufacturers of Others Table 37. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application 2021 VS 2025 VS 2032 (Units) Table 38. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application (2021-2026) & (Units) Table 39. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application (2027-2032) & (Units) Table 40. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Application (2021-2026) Table 41. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Application (2027-2032) Table 42. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 43. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application (2021-2026) & (Units) Table 44. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application (2027-2032) & (Units) Table 45. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Application (2021-2026) Table 46. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Application (2027-2032) Table 47. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 48. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2021-2026) & (Units) Table 49. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Region (2021-2026) Table 50. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Forecasted by Region (2027-2032) & (Units) Table 51. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 53. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026) & (Units) Table 54. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032) & (Units) Table 55. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 56. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026) & (Units) Table 57. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032) & (Units) Table 58. Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 59. Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026) & (Units) Table 60. Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032) & (Units) Table 61. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 62. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2026) & (Units) Table 63. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2027-2032) & (Units) Table 64. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Region (2021-2026) Table 68. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Region (2027-2032) Table 69. LEAD CHEMICAL Company Information Table 70. LEAD CHEMICAL Business Overview Table 71. LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 73. LEAD CHEMICAL Recent Development Table 74. Merck KGaA Company Information Table 75. Merck KGaA Business Overview Table 76. Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 78. Merck KGaA Recent Development Table 79. Verona Pharma Company Information Table 80. Verona Pharma Business Overview Table 81. Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 83. Verona Pharma Recent Development Table 84. Arcutis Company Information Table 85. Arcutis Business Overview Table 86. Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 88. Arcutis Recent Development Table 89. GlaxoSmithKline PLc Company Information Table 90. GlaxoSmithKline PLc Business Overview Table 91. GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 93. GlaxoSmithKline PLc Recent Development Table 94. Huadong Medicine Company Information Table 95. Huadong Medicine Business Overview Table 96. Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 98. Huadong Medicine Recent Development Table 99. Pfizer Inc. Company Information Table 100. Pfizer Inc. Business Overview Table 101. Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 103. Pfizer Inc. Recent Development Table 104. Roche Company Information Table 105. Roche Business Overview Table 106. Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 108. Roche Recent Development Table 109. MSD Company Information Table 110. MSD Business Overview Table 111. MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 113. MSD Recent Development Table 114. Genzyme Co. Company Information Table 115. Genzyme Co. Business Overview Table 116. Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 118. Genzyme Co. Recent Development Table 119. Shapuaisi Company Information Table 120. Shapuaisi Business Overview Table 121. Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 123. Shapuaisi Recent Development Table 124. Sato Pharmaceutical Company Information Table 125. Sato Pharmaceutical Business Overview Table 126. Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio Table 128. Sato Pharmaceutical Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Dermatological Non-Steroidal Anti-Inflammatory Drugs Distributors List Table 132. Dermatological Non-Steroidal Anti-Inflammatory Drugs Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Image Figure 2. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales (2021-2032) & (Units) Figure 5. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Dermatological Non-Steroidal Anti-Inflammatory Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ketotifen Image Figure 9. Ketoconazole Image Figure 10. Phthalin Butan Image Figure 11. Tacrolimus Image Figure 12. Prednisone Image Figure 13. Loratadine Image Figure 14. Cyclosporine A Image Figure 15. Others Image Figure 16. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 17. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Type (2021-2032) Figure 19. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 20. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Type (2021-2032) Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Others Image Figure 25. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 26. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Application (2021-2032) Figure 28. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 29. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Application (2021-2032) Figure 31. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 32. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2021-2032) Figure 33. U.S. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 34. Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 35. Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 36. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 37. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2021-2032) Figure 38. Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 39. France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 40. U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 41. Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 42. Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 43. Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 44. Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2021-2032) Figure 45. China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 46. Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 47. South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 48. Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 49. India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 50. Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 51. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 52. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Country (2021-2032) Figure 53. Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 54. South Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 55. Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 56. Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 57. Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 58. UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 59. Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 60. Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales and Growth Rate (2021-2032) & (Units) Figure 61. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032) & (US$ Million) Figure 64. North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Dermatological Non-Steroidal Anti-Inflammatory Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Dermatological Non-Steroidal Anti-Inflammatory Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Ketotifen
  • Ketoconazole
  • Phthalin Butan
  • Tacrolimus
  • Prednisone
  • Loratadine
  • Cyclosporine A
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • LEAD CHEMICAL
  • Merck KGaA
  • Verona Pharma
  • Arcutis
  • GlaxoSmithKline PLc
  • Huadong Medicine
  • Pfizer Inc.
  • Roche
  • MSD
  • Genzyme Co.
  • Shapuaisi
  • Sato Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Dynamics
  1. 2.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Trends
  2. 2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Drivers
  3. 2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Opportunities and Challenges
  4. 2.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Restraints
3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Manufacturers
  1. 3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dermatological Non-Steroidal Anti-Inflammatory Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dermatological Non-Steroidal Anti-Inflammatory Drugs Tier 1, Tier 2, and Tier 3
4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Type
  1. 4.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Type Introduction
  2. 4.1.1 Ketotifen
  3. 4.1.2 Ketoconazole
  4. 4.1.3 Phthalin Butan
  5. 4.1.4 Tacrolimus
  6. 4.1.5 Prednisone
  7. 4.1.6 Loratadine
  8. 4.1.7 Cyclosporine A
  9. 4.1.8 Others
  10. 4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type
  11. 4.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Type (2021-2032)
  13. 4.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Type (2021-2032)
  14. 4.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type
  15. 4.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Type (2021-2032)
  17. 4.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Type (2021-2032)
5 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Application
  1. 5.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application
  6. 5.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application
  10. 5.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Application (2021-2032)
6 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region
  1. 6.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region
  1. 7.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region
  2. 7.1.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032)
  8. 7.2.2 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 LEAD CHEMICAL
  2. 8.1.1 LEAD CHEMICAL Company Information
  3. 8.1.2 LEAD CHEMICAL Business Overview
  4. 8.1.3 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  6. 8.1.5 LEAD CHEMICAL Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Verona Pharma
  14. 8.3.1 Verona Pharma Company Information
  15. 8.3.2 Verona Pharma Business Overview
  16. 8.3.3 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  18. 8.3.5 Verona Pharma Recent Developments
  19. 8.4 Arcutis
  20. 8.4.1 Arcutis Company Information
  21. 8.4.2 Arcutis Business Overview
  22. 8.4.3 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  24. 8.4.5 Arcutis Recent Developments
  25. 8.5 GlaxoSmithKline PLc
  26. 8.5.1 GlaxoSmithKline PLc Company Information
  27. 8.5.2 GlaxoSmithKline PLc Business Overview
  28. 8.5.3 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline PLc Recent Developments
  31. 8.6 Huadong Medicine
  32. 8.6.1 Huadong Medicine Company Information
  33. 8.6.2 Huadong Medicine Business Overview
  34. 8.6.3 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  36. 8.6.5 Huadong Medicine Recent Developments
  37. 8.7 Pfizer Inc.
  38. 8.7.1 Pfizer Inc. Company Information
  39. 8.7.2 Pfizer Inc. Business Overview
  40. 8.7.3 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  42. 8.7.5 Pfizer Inc. Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 MSD
  50. 8.9.1 MSD Company Information
  51. 8.9.2 MSD Business Overview
  52. 8.9.3 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  54. 8.9.5 MSD Recent Developments
  55. 8.10 Genzyme Co.
  56. 8.10.1 Genzyme Co. Company Information
  57. 8.10.2 Genzyme Co. Business Overview
  58. 8.10.3 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  60. 8.10.5 Genzyme Co. Recent Developments
  61. 8.11 Shapuaisi
  62. 8.11.1 Shapuaisi Company Information
  63. 8.11.2 Shapuaisi Business Overview
  64. 8.11.3 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  66. 8.11.5 Shapuaisi Recent Developments
  67. 8.12 Sato Pharmaceutical
  68. 8.12.1 Sato Pharmaceutical Company Information
  69. 8.12.2 Sato Pharmaceutical Business Overview
  70. 8.12.3 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
  72. 8.12.5 Sato Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Value Chain Analysis
  2. 9.1.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Production Mode & Process
  6. 9.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Distributors
  9. 9.2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst